Clinical trials: Negative Symptoms of Schizophrenia
Schizophrenia
Pilot Study of Pregnenolone Augmentation Targeting Cognitive Symptoms in Persistently Symptomatic Patients With Schizophrenia
This is a pilot study of pregnenolone as an augmentation treatment for schizophrenia. The goal of this placebo-controlled study is to provide preliminary efficacy data for potential pregnenolone effects on cognitive symptoms and…
- Trial name
- NCT00560937
- Testing
- Pregnenolone
- Where
- United States
- Volunteers
- 28 people
- Sponsor
- Durham VA Medical Center
Schizophrenia, Schizoaffective Disorder
D-Serine Treatment of Negative Symptoms and Cognitive Deficits in Schizophrenia
This study is based on the hypothesis that by increasing N-methyl-D-aspartic acid (NMDA) receptor function in the brain and thereby increasing the capacity of the brain to both form new connections and strengthen existing…
- Trial name
- NCT00237809
- Testing
- D-serine, Cognitive Retraining (CRT)
- Where
- 2 sites in United States
- Volunteers
- 104 people
- Sponsor
- Yale University
Negative Symptoms of Schizophrenia
SPD489 as Adjunctive Treatment in Adults With Negative Symptoms of Schizophrenia
To assess the safety and efficacy of SPD489 low-dose and high-dose treatment groups to placebo when given as adjunctive therapy to antipsychotic medication in clinically stable adults with persistent predominant negative symptoms…
- Trial name
- NSS (NCT01234298)
- Testing
- SPD489 Low-Dose, SPD489 High-Dose
- Sponsor
- Shire
Schizophrenia
A Study Of PF-03463275 As Add-On Therapy In Outpatients With Persistent Negative Symptoms Of Schizophrenia
This study is examining the efficacy of PF-03463275 compared to placebo in treating negative symptoms of schizophrenia when added to ongoing antipsychotic treatment in stable outpatients with schizophrenia.
- Trial name
- NCT00977522
- Testing
- PF-03463275
- Where
- 37 sites in United States
- Volunteers
- 207 people
- Sponsor
- Pfizer
Schizophrenia
The Efficacy and Safety of a Selective Estrogen Receptor Beta Agonist (LY500307) for Negative Symptoms and Cognitive Impairment Associated With Schizophrenia
The primary objectives of this application are to determine if the selective ERβ agonist LY500307, when added to antipsychotic medications, improves negative and/or cognitive symptoms in patients with schizophrenia.
- Trial name
- Beta (NCT01874756)
- Testing
- LY500307 150mg, LY500307 75mg, LY500307 25mg
- Where
- 4 sites in United States
- Volunteers
- 95 people
- Sponsor
- Indiana University
Schizoaffective Disorder, Schizophrenia
Genetic Study of Schizophrenia
This large ongoing study at NIMH investigates the neurobiology of schizophrenia by identifying susceptibility genes, evaluating their impact on brain function to better understand how to treat and prevent this illness.
- Trial name
- NCT00001486
- Where
- United States
- Volunteers
- 4,914 people
- Sponsor
- National Institute of Mental Health (NIMH)
Schizophrenia
Efficacy and Safety of Pimavanserin as Adjunctive Treatment for the Negative Symptoms of Schizophrenia (ADVANCE)
To evaluate the efficacy and safety of adjunctive pimavanserin compared with adjunctive placebo in the treatment of the negative symptoms of schizophrenia
- Trial name
- NCT02970305
- Testing
- Pimavanserin
- Where
- 101 sites in United States, Bulgaria and 8 more
- Volunteers
- 403 people
- Sponsor
- ACADIA Pharmaceuticals Inc.
Schizophrenia, Depression
Characterization of the Motivational Deficit in Schizophrenia and Depression
This research focuses on disorders of motivation, responsible for a disability that patients experience daily. It is a disorder that affects behavior, especially social.
- Trial name
- SCHIZOBAT (NCT02378818)
- Testing
- Force task, preference task, discount task, learning task.
- Where
- France
- Volunteers
- 140 people, healthy volunteers welcome
- Sponsor
- Centre Hospitalier St Anne
Schizophrenia, Negative Symptoms in Schizophrenia
A Study on the Efficacy of Agomelatine Combined With Antipsychotics to Treat Negative Symptoms in Schizophrenia
This study is a prospective, multicenter, controlled, real world study. Patients will be randomly enrolled into the test group and the control group at a ratio of 1:1 during the screening period.
- Trial name
- NCT05646264
- Testing
- Agomelatine
- Where
- China
- Volunteers
- 220 people
- Sponsor
- Shanghai Mental Health Center
Schizophrenia Disorders, Psychotic Disorder
Effect of Melatonin on Schizophrenic Symptoms: a Randomized Placebo-Controlled Trial
Schizophrenia is a chronic mental health disorder that affects thoughts, emotions, and behaviors. It includes positive symptoms such as hallucinations and delusions, as well as negative symptoms like reduced motivation, social…
- Trial name
- NCT06838104
- Testing
- Melatonin
- Where
- Pakistan
- Volunteers
- 76 people
- Sponsor
- Lahore General Hospital
Schizophrenia, Schizoaffective Disorder
Clinical Trial of Dipyridamole in Schizophrenia
This is a 6-week, randomized, double blind, parallel groups designed, olanzapine-controlled trial of oral dipyridamole in symptomatic patients with a (DSM IV) diagnosis of schizophrenia, schizoaffective or schizophreniform…
- Conditions
- Schizophrenia, Schizoaffective Disorder, Schizophreniform Disorder
- Trial name
- NCT00349973
- Testing
- Dipyridamole, Olanzapine
- Where
- United States
- Volunteers
- 29 people
- Sponsor
- University of Maryland, Baltimore
Schizophrenia
Antidepressant Controlled Trial for Negative Symptoms in Schizophrenia
The aim of this double-blind, placebo-controlled trial is to establish the clinical and cost effectiveness of an SSRI antidepressant, citalopram, in the management of persistent negative symptoms of schizophrenia over a year.
- Trial name
- ACTIONS (NCT01032083)
- Testing
- Citalopram
- Where
- 14 sites in United Kingdom
- Volunteers
- 62 people
- Sponsor
- Imperial College London
Schizophrenia
Effect of Quetiapine on Negative Symptoms and Cognition
The purpose of the study is to investigate the outcome on negative symptoms of schizophrenic patients during therapy with quetiapine or risperidone.
- Trial name
- NCT00305422
- Testing
- Quetiapine fumarate, Risperidone
- Where
- Germany
- Volunteers
- 45 people
- Sponsor
- AstraZeneca
Schizophrenia Spectrum and Other Psychotic Disorders
Plan D- Vitamin D Supplementation in Psychotic Disorders
Background: Impairment in cognitive processing speed is a consistent finding in schizophrenia spectrum disorder. Vitamin D deficiency is found to be significantly associated with reduced processing speed.
- Trial name
- NCT05211635
- Testing
- Vitamin D
- Where
- Norway
- Volunteers
- 14 people
- Sponsor
- University Hospital, Akershus
Schizophrenia
Evaluation of the H1-coil Deep TMS in the Treatment of Negative Symptoms and Cognitive Deficit in Schizophrenia
The study evaluates the feasibility of using a 4 week stimulation protocol with the deep TMS H-coils for the treatment of negative symptoms and cognitive deficit in schizophrenia patients
- Trial name
- NCT00445926
- Testing
- deep TMS H-coil
- Where
- Israel
- Sponsor
- Shalvata Mental Health Center
Negative Symptoms With Primary Psychotic Disorder, Schizophrenia
rTMS Add on Value for Amelioration of Negative Symptoms of Schizophrenia
Treatment of depression with repetitive transcranial magnetic stimulation (rTMS) has shown high evidence using high-frequency left dorsolateral prefrontal cortex (DLPFC) stimulation.
- Trial name
- RADOVAN (NCT04318977)
- Testing
- high-frequency rTMS, TBS
- Where
- 4 sites in Czechia, Germany
- Volunteers
- 62 people
- Sponsor
- University of Regensburg
Schizophrenia, Schizo Affective Disorder
Intervention Targeting Motivational Negative Symptoms
This study aims to investigate the effects of the Switch intervention on motivation and associated processes and explore the dynamics between the processes.
- Conditions
- Schizophrenia, Schizo Affective Disorder, Bipolar Disorder, Major Depressive Disorder
- Trial name
- Switch (NCT04325100)
- Testing
- Switch - Individual sessions, Switch - Group programme
- Where
- Belgium
- Volunteers
- 13 people
- Sponsor
- University of Liege
Schizophrenia
Efficiency of the French Translation Social Cognition and Interactive Training (SCIT)Program
Social cognition and interaction training (SCIT), a group-based treatment that aims to improve both processing social information and functioning, may be an effective treatment for enhancing the social skills of people with…
- Trial name
- SCIT-VF (NCT02667834)
- Testing
- Social Cognition and Interaction Training (SCIT), therapeutic education program (ETP)
- Where
- France
- Volunteers
- 103 people
- Sponsor
- Hôpital le Vinatier
Schizophrenia
6-Month Extension Trial of Asenapine With Olanzapine in Negative Symptoms Patients Who Completed the First 6- Month Trial (A7501014)(COMPLETED)(P05772)
This is an extension study of A7501013 (P05771/NCT00145496) to further test the efficacy and safety of Asenapine compared with a marketed agent (olanzapine) in the treatment of patients with persistent negative symptoms of…
- Trial name
- NCT00174265
- Testing
- asenapine, olanzapine
- Volunteers
- 196 people
- Sponsor
- Organon and Co
Schizophrenia
A Study of RO4917838 in Participants With Persistent, Predominant Negative Symptoms of Schizophrenia (NN25310)
This multi-center, randomized, double-blind, parallel-group, placebo-controlled study will evaluate the efficacy and safety of RO4917838 in participants with persistent, predominant negative symptoms of schizophrenia.
- Trial name
- NCT01192867
- Testing
- RO4917838, Antipshychotics (Standard of Care)
- Where
- 122 sites in United States, Argentina and 12 more
- Volunteers
- 629 people
- Sponsor
- Hoffmann-La Roche